NEOS stock forecast
Our latest prediction for Neos Therapeutics, Inc.'s stock price was made on the Dec. 12, 2018 when the stock price was at 2.04$.
In the short term (2weeks), NEOS's stock price should outperform the market by 5.26%. During that period the price should oscillate between -10.04% and +21.31%.
In the medium term (3months), NEOS's stock price should outperform the market by 12.43%. During that period the price should oscillate between -22.74% and +53.03%.Get email alerts
About Neos Therapeutics, Inc.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
At the moment the company generates 42M USD in revenues.
On its last earning announcement, the company reported a loss of -1.90$ per share.
The book value per share is -0.63$
Three months stock forecastDec. 12, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|